Breaking News Bar
updated: 5/8/2013 10:43 AM

Takeda to acquire Inviragen for $250 million

hello
Success - Article sent! close
  • Deerfield-based Takeda Pharmaceutical Co. said its U.S. subsidiary, Takeda America Holdings, Inc., awill acquire biopharmaceutical company Inviragen for an estimated total of $250 million.

      Deerfield-based Takeda Pharmaceutical Co. said its U.S. subsidiary, Takeda America Holdings, Inc., awill acquire biopharmaceutical company Inviragen for an estimated total of $250 million.

 
PRNewswire

Deerfield-based Takeda Pharmaceutical Co. said its U.S. subsidiary, Takeda America Holdings, Inc., awill acquire biopharmaceutical company Inviragen for an estimated total of $250 million.

Takeda said it will make an upfront payment of $35 million, and future payments of up to $215 million that are linked to the progress of clinical development and achievement of key commercial milestones, according to a release.

Headquartered in Fort Collins, Colo., with facilities in Madison, Wis. and Singapore, Inviragen is a privately-held biopharmaceutical company specializing in research and development of innovative vaccines for emerging infectious diseases, including dengue and hand, foot and mouth disease.

"Takeda has taken another major step toward its goal of establishing a world-class global vaccine business by acquiring Inviragen and its advanced vaccine candidate against dengue, a serious mosquito-borne illness that threatens nearly half of the world's population," said Rajeev Venkayya, M.D., executive vice president and head of Takeda's Vaccine Business Division.

Inviragen has created innovative products using its expertise in viral vaccines, including a vaccine for the prevention of dengue infection. The company is also looking at vaccines to protect against hand, foot and mouth disease and chikungunya.

"The acquisition of Inviragen supports Takeda's overall research and development programs, long-term growth strategy and commitment to improve health through innovation and new technology," said Tadataka Yamada, M.D., Takeda's chief medical and scientific officer and member of the Takeda board of directors. "Coming less than a year after the acquisition of LigoCyte with the world's leading norovirus vaccine candidate, this illustrates Takeda's commitment to its global vaccine business and global public health."

Share

Interested in reusing this article?

Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.

The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.

Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Name * Company Telephone * E-mail *

Message (optional)

Success - Reprint request sent Click to close
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here